JP2002532551A - 新規製剤 - Google Patents

新規製剤

Info

Publication number
JP2002532551A
JP2002532551A JP2000589192A JP2000589192A JP2002532551A JP 2002532551 A JP2002532551 A JP 2002532551A JP 2000589192 A JP2000589192 A JP 2000589192A JP 2000589192 A JP2000589192 A JP 2000589192A JP 2002532551 A JP2002532551 A JP 2002532551A
Authority
JP
Japan
Prior art keywords
formulation
cycloheptene
dibenzo
dihydro
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000589192A
Other languages
English (en)
Japanese (ja)
Inventor
アンデルセン、ティナ・マイナーツ
ヒョルテ、ティーゲ・ボルプ
ジョルゲンセン、キム・ウェスティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2002532551A publication Critical patent/JP2002532551A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000589192A 1998-12-22 1999-12-14 新規製剤 Pending JP2002532551A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK199801703 1998-12-22
DKPA199801703 1998-12-22
PCT/DK1999/000699 WO2000037081A1 (fr) 1998-12-22 1999-12-14 Nouvelle formulation

Publications (1)

Publication Number Publication Date
JP2002532551A true JP2002532551A (ja) 2002-10-02

Family

ID=8107354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000589192A Pending JP2002532551A (ja) 1998-12-22 1999-12-14 新規製剤

Country Status (4)

Country Link
EP (1) EP1140084A1 (fr)
JP (1) JP2002532551A (fr)
AU (1) AU1649700A (fr)
WO (1) WO2000037081A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532985A (ja) * 2001-10-25 2005-11-04 ディポメド，インコーポレイティド 胃内滞留性錠剤用の最適ポリマー混合物
JP2015091864A (ja) * 2005-06-10 2015-05-14 ノバルティス アーゲー 放出が改良された１−［（３−ヒドロキシ−アダマント−１−イルアミノ）−アセチル］−ピロリジン−２（ｓ）−カルボニトリル製剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114533699B (zh) * 2021-12-15 2023-05-26 南通联亚药业股份有限公司 一种盐酸环苯扎林缓释胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
JP3048067B2 (ja) * 1995-12-15 2000-06-05 ノボ ノルディスク アクティーゼルスカブ 新規方法
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532985A (ja) * 2001-10-25 2005-11-04 ディポメド，インコーポレイティド 胃内滞留性錠剤用の最適ポリマー混合物
JP2015091864A (ja) * 2005-06-10 2015-05-14 ノバルティス アーゲー 放出が改良された１−［（３−ヒドロキシ−アダマント−１−イルアミノ）−アセチル］−ピロリジン−２（ｓ）−カルボニトリル製剤
JP2016222675A (ja) * 2005-06-10 2016-12-28 ノバルティス アーゲー 放出が改良された１−［（３−ヒドロキシ−アダマント−１−イルアミノ）−アセチル］−ピロリジン−２（ｓ）−カルボニトリル製剤
JP2018172392A (ja) * 2005-06-10 2018-11-08 ノバルティス アーゲー 放出が改良された１−［（３−ヒドロキシ−アダマント−１−イルアミノ）−アセチル］−ピロリジン−２（ｓ）−カルボニトリル製剤
JP2020055816A (ja) * 2005-06-10 2020-04-09 ノバルティス アーゲー 放出が改良された１−［（３−ヒドロキシ−アダマント−１−イルアミノ）−アセチル］−ピロリジン−２（ｓ）−カルボニトリル製剤

Also Published As

Publication number Publication date
WO2000037081A1 (fr) 2000-06-29
EP1140084A1 (fr) 2001-10-10
AU1649700A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
JP2986546B2 (ja) スマトリプタンを含有する組成物
US20180344695A1 (en) Sustained release pharmaceutical compositions
EP1458377B1 (fr) Compositions pharmaceutiques renfermant tegaserod
KR101858797B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
JPH11507958A (ja) 徐放性ヘテロ分散ヒドロゲル系―非晶薬物
NZ528738A (en) Composition comprising nateglinide for treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US20100209511A1 (en) sustained release pharmaceutical formulation
KR20130030261A (ko) 활성제-무함유 과립 및 그를 포함하는 정제의 제조
EP4074308A1 (fr) Formulation elagolix
EP2124891A1 (fr) Préparation à libération contrôlée contenant du cilostazol et son procédé de fabrication
NO320022B1 (no) Kontrollert frigjorende farmasoytisk preparat med tilidinmesylat som virkestoff
WO2006103551A1 (fr) Formulations d’oxycodone a liberation controlee
US20090264408A1 (en) Extended release dosage forms of quetiapine
CZ124497A3 (en) Oral preparations with prolonged release of cisaprid
KR20010061927A (ko) 라소폭시펜의 투여요법
JP2002538197A (ja) ベタヒスチンの徐放性組成物
JP2002532551A (ja) 新規製剤
JP2847866B2 (ja) 消化性潰瘍治療剤
US6680067B2 (en) Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same
EP2839829B1 (fr) Comprimé à libération prolongée contenant de la lévodropropizine et procédé pour préparer celui-ci
KR100504618B1 (ko) 향상된 생체 이용율을 갖는 에르고트 알칼로이드의 서방형약제학적 조성물의 제조방법 및 그들의 조성물
EP2269586B1 (fr) Composition pharmaceutique comprenant du desloratadine
US6207682B1 (en) Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid
JP2001511450A (ja) チアガビンを含有する制御放出性の医薬組成物
WO2008032208A2 (fr) Formulation à libération prolongée d'un agent antiépileptique